Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
BridgeBio Pharma, Inc. | 10%+ Owner | Common Stock | 25.1M | $954M | $37.97 | Jul 18, 2023 | Indirect |
Roivant Sciences Ltd. | 10%+ Owner | Common Shares | 12.9M | $133M | $10.35 | Jun 22, 2023 | Indirect |
FIGS, Inc. | 10%+ Owner | Class A Common Stock | 14.7M | $89.6M | $6.08 | Sep 3, 2021 | Indirect |
Ginkgo Bioworks Holdings, Inc. | 10%+ Owner | Class A Common Stock | 51.1M | $79.4M | $1.56 | Mar 2, 2022 | Indirect |
4D Molecular Therapeutics, Inc. | 10%+ Owner | Common Stock | 4.25M | $78.2M | $18.41 | Jan 4, 2024 | Indirect |
STANDARD BIOTOOLS INC. | 10%+ Owner | Common Stock | 19.4M | $53.2M | $2.75 | Mar 18, 2024 | Indirect |
Amylyx Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 1.85M | $30.2M | $16.33 | Sep 9, 2022 | Indirect |
PROCEPT BioRobotics Corp | 10%+ Owner | Common Stock | 298K | $13.4M | $44.97 | Mar 18, 2022 | Indirect |
Frazier Lifesciences Acquisition Corp | 10%+ Owner | Common Stock | 1.21M | $12.2M | $10.08 | Nov 2, 2022 | Indirect |
Inhibrx Biosciences, Inc. | 10%+ Owner | Common Stock | 128K | $1.65M | $12.93 | May 29, 2024 | Indirect |
APi Group Corp | 10%+ Owner | Common Stock | 0 | $0 | $38.15 | Jun 17, 2024 | Indirect |
Inhibrx, Inc. | 10%+ Owner | Common Stock | 0 | $0 | $30.00 | May 30, 2024 | Indirect |
Inhibrx, Inc. | 10%+ Owner | Warrants (right to buy) | 0 | $0 | $30.00 | May 30, 2024 | Indirect |
RayzeBio, Inc. | 10%+ Owner | Common Stock | 0 | $0 | $62.50 | Feb 26, 2024 | Indirect |
Ginkgo Bioworks Holdings, Inc. | 10%+ Owner | Class C Common Stock | 288M | Mar 2, 2022 | Indirect | ||
Rallybio Corp | 10%+ Owner | Pre-Funded Warrants to Purchase Common Stock | 3.33M | Nov 15, 2022 | Indirect | ||
APi Group Corp | 10%+ Owner | 5.5% Series B Perpetual Convertible Preferred Stock | 0 | Feb 28, 2024 | Indirect | ||
Frazier Lifesciences Acquisition Corp | 10%+ Owner | Class A Ordinary Shares | 0 | Nov 22, 2022 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series C Convertible Preferred Stock | 0 | Sep 19, 2023 | Indirect | ||
RayzeBio, Inc. | 10%+ Owner | Series D Convertible Preferred Stock | 0 | Sep 19, 2023 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
APG | APi Group Corp | Jun 17, 2024 | 2 | -$74.5M | 4 | Jun 18, 2024 | 10%+ Owner |
APG | APi Group Corp | Jun 17, 2024 | 2 | -$74.5M | 4 | Jun 18, 2024 | 10%+ Owner |
INBX | Inhibrx, Inc. | May 30, 2024 | 4 | -$246M | 4 | Jun 3, 2024 | 10%+ Owner |
INXB | Inhibrx Biosciences, Inc. | May 29, 2024 | 0 | $0 | 3 | Jun 7, 2024 | 10%+ Owner |
LAB | STANDARD BIOTOOLS INC. | Mar 18, 2024 | 0 | $0 | 3 | Mar 20, 2024 | 10%+ Owner |
APG | APi Group Corp | Mar 5, 2024 | 2 | -$104M | 4 | Mar 7, 2024 | 10%+ Owner |
APG | APi Group Corp | Mar 5, 2024 | 2 | -$104M | 4 | Mar 7, 2024 | 10%+ Owner |
APG | APi Group Corp | Feb 28, 2024 | 6 | $51.7M | 4 | Mar 1, 2024 | 10%+ Owner |
APG | APi Group Corp | Feb 28, 2024 | 6 | $51.7M | 4 | Mar 1, 2024 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Feb 26, 2024 | 2 | $0 | 4 | Feb 28, 2024 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Feb 26, 2024 | 2 | $0 | 4 | Feb 28, 2024 | 10%+ Owner |
FDMT | 4D Molecular Therapeutics, Inc. | Jan 4, 2024 | 1 | -$10.5M | 4 | Jan 5, 2024 | 10%+ Owner |
APG | APi Group Corp | Jan 2, 2024 | 3 | -$203M | 4 | Jan 4, 2024 | 10%+ Owner |
APG | APi Group Corp | Jan 2, 2024 | 3 | -$203M | 4 | Jan 4, 2024 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 19, 2023 | 10 | $25M | 4 | Sep 21, 2023 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 19, 2023 | 10 | $25M | 4 | Sep 21, 2023 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | 10%+ Owner |
RYZB | RayzeBio, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | 10%+ Owner |
INBX | Inhibrx, Inc. | Aug 28, 2023 | 2 | $30M | 4 | Aug 30, 2023 | 10%+ Owner |
BBIO | BridgeBio Pharma, Inc. | Jul 18, 2023 | 1 | -$52.5M | 4 | Jul 19, 2023 | 10%+ Owner |
ROIV | Roivant Sciences Ltd. | Jun 22, 2023 | 4 | -$129M | 4 | Jun 26, 2023 | 10%+ Owner |
FDMT | 4D Molecular Therapeutics, Inc. | May 9, 2023 | 1 | $13.6M | 4 | May 11, 2023 | 10%+ Owner |
FLAC | Frazier Lifesciences Acquisition Corp | Nov 22, 2022 | 2 | $0 | 4 | Nov 25, 2022 | 10%+ Owner |
RLYB | Rallybio Corp | Nov 15, 2022 | 1 | $20M | 4 | Nov 17, 2022 | 10%+ Owner |
FLAC | Frazier Lifesciences Acquisition Corp | Nov 2, 2022 | 2 | $8.54M | 4 | Nov 4, 2022 | 10%+ Owner |
FLAC | Frazier Lifesciences Acquisition Corp | Nov 1, 2022 | 0 | $0 | 3 | Nov 4, 2022 | 10%+ Owner |
INBX | Inhibrx, Inc. | Oct 7, 2022 | 2 | $40M | 4 | Oct 12, 2022 | 10%+ Owner |
AMLX | Amylyx Pharmaceuticals, Inc. | Sep 8, 2022 | 16 | -$41.7M | 4 | Sep 9, 2022 | 10%+ Owner |
PRCT | PROCEPT BioRobotics Corp | Mar 18, 2022 | 2 | -$37.3M | 4 | Mar 22, 2022 | 10%+ Owner |
DNA | Ginkgo Bioworks Holdings, Inc. | Mar 2, 2022 | 2 | $0 | 4 | Mar 4, 2022 | 10%+ Owner |
AMLX | Amylyx Pharmaceuticals, Inc. | Jan 11, 2022 | 3 | $43.7M | 4 | Jan 13, 2022 | 10%+ Owner |
AMLX | Amylyx Pharmaceuticals, Inc. | Jan 6, 2022 | 0 | $0 | 3 | Jan 11, 2022 | 10%+ Owner |
APG | APi Group Corp | Jan 3, 2022 | 2 | $200M | 4 | Jan 5, 2022 | 10%+ Owner |
ROIV | Roivant Sciences Ltd. | Oct 1, 2021 | 0 | $0 | 3 | Oct 1, 2021 | 10%+ Owner |
PRCT | PROCEPT BioRobotics Corp | Sep 17, 2021 | 7 | $14M | 4 | Sep 21, 2021 | 10%+ Owner |
DNA | Ginkgo Bioworks Holdings, Inc. | Sep 16, 2021 | 0 | $0 | 3 | Sep 23, 2021 | 10%+ Owner |
PRCT | PROCEPT BioRobotics Corp | Sep 14, 2021 | 0 | $0 | 3 | Sep 14, 2021 | 10%+ Owner |
FIGS | FIGS, Inc. | Sep 2, 2021 | 2 | -$9.36M | 4 | Sep 3, 2021 | 10%+ Owner |
RLYB | Rallybio Corp | Jul 29, 2021 | 3 | $10.5M | 4 | Aug 2, 2021 | 10%+ Owner |
RLYB | Rallybio Corp | Jul 29, 2021 | 0 | $0 | 3 | Jul 29, 2021 | 10%+ Owner |
FIGS | FIGS, Inc. | May 26, 2021 | 0 | $0 | 3 | Jun 7, 2021 | 10%+ Owner |